Cancer Genetics and High Risk Program, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
Department of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
JCO Precis Oncol. 2022 Mar;6:e2100444. doi: 10.1200/PO.21.00444.
The SickKids Cancer Sequencing (KiCS) Program, launched in 2016, evaluates the clinical utility of paired tumor/germline Next-Generation Sequencing (NGS) in pediatric oncology patients with hard-to-cure and rare cancers. In anticipation of further widespread adoption of NGS, we aimed to characterize the experiences and perspectives of adolescents and parents of patients who have already undergone NGS evaluation, focusing on the psychosocial impact and personal utility.
Parents of patients with pediatric cancer and adolescent patients who have participated in KiCS were invited to participate in semistructured interviews. Transcripts were analyzed using an inductive content analytic approach.
Of 45 individuals invited, 22 parents and 10 adolescents were interviewed (71% response rate). Prominent psychosocial themes were low distress, relief, and sense of control; some expressed fear of the unknown. In exploring constructs of personal utility, parents highlighted hope for treatment options despite low expectations for results with clinical impact, whereas adolescents articulated altruistic motivations and less hope for personal clinical benefit. Bringing closure and answering the question of why the cancer occurred was a salient theme among both groups. Both parents and adolescents find benefit and clear decisional satisfaction with participation. No participants expressed regret.
This study suggests that parents and adolescents benefit from NGS evaluation beyond the return of clinically relevant results. Our findings lay the framework for future work evaluating the value of NGS in pediatric precision oncology care through assessment of patient-reported outcomes and experiences. These results also guide provision of pre- and post-test education and support, which will facilitate patient-centered delivery of NGS practices.
SickKids Cancer Sequencing(KiCS)计划于 2016 年启动,评估了下一代测序(NGS)在儿科肿瘤学中对治疗困难和罕见癌症患者的肿瘤/种系配对的临床应用。预计 NGS 将进一步广泛采用,我们旨在描述已经接受 NGS 评估的患者的青少年和父母的经验和观点,重点关注心理社会影响和个人效用。
邀请参加 KiCS 的儿科癌症患者的父母和青少年患者参加半结构化访谈。使用归纳内容分析方法对转录本进行分析。
在 45 名受邀者中,有 22 名父母和 10 名青少年接受了采访(71%的回应率)。突出的心理社会主题是低压力、缓解和控制感;有些人表达了对未知的恐惧。在探索个人效用的结构时,父母强调了治疗选择的希望,尽管对具有临床影响的结果的期望较低,而青少年则表达了利他主义的动机和对个人临床获益的较少希望。为癌症发生寻找答案和带来结束感是两组共同的突出主题。父母和青少年都从参与中获得了好处和明确的决策满意度。没有参与者表示后悔。
这项研究表明,父母和青少年从 NGS 评估中获益,不仅限于获得临床相关结果。我们的发现为未来通过评估患者报告的结果和经验来评估 NGS 在儿科精准肿瘤学护理中的价值奠定了基础。这些结果还指导了检测前和检测后的教育和支持的提供,这将有助于以患者为中心提供 NGS 实践。